Despite low growth, undervalued Huntsman shares might be a good investment. However, the company's financial health is also key to consider. Its future outlook is possibly not fully reflected yet, offering a potentially attractive opportunity.
Huntsman's low P/S ratio is down to limited revenue growth predictions. Failure to increase its revenue might keep its share price low and possibly lower P/S levels.
Huntsman's stagnant business growth, marked by a declining ROCE and stable capital employed, dampens its investment appeal despite a robust 43% stock return over five years.
Gapping up In reaction to earnings/guidance: •$Bowlero(BOWL.US)$+3.4% Other news: •$Intellia Therapeutics(NTLA.US)$+10.8% (Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002) •$Gogo Inc(GOGO.US)$+5% (Repurchases 1.5 million shares of common stock from BlackRock) •$ADC Therapeutics(ADCT.US)$+2.9% (ADC Therapeutics and Swedish Orphan Biovitrum AB (BIOVF) confirms positive CHM...